EP3021663A4 - Souris transgénique exprimant la lipoprotéine (a) humaine avec gène de la vitamine c désactivé et son utilisation comme modèle de traitement de maladie - Google Patents

Souris transgénique exprimant la lipoprotéine (a) humaine avec gène de la vitamine c désactivé et son utilisation comme modèle de traitement de maladie

Info

Publication number
EP3021663A4
EP3021663A4 EP14830365.4A EP14830365A EP3021663A4 EP 3021663 A4 EP3021663 A4 EP 3021663A4 EP 14830365 A EP14830365 A EP 14830365A EP 3021663 A4 EP3021663 A4 EP 3021663A4
Authority
EP
European Patent Office
Prior art keywords
disabled
vitamin
gene
transgenic mouse
expressing human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14830365.4A
Other languages
German (de)
English (en)
Other versions
EP3021663A1 (fr
EP3021663B1 (fr
Inventor
Matthias W Rath
Aleksandra Niedzwiecki
John Chang-Eun Cha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/506,674 external-priority patent/US20150074835A1/en
Application filed by Individual filed Critical Individual
Publication of EP3021663A1 publication Critical patent/EP3021663A1/fr
Publication of EP3021663A4 publication Critical patent/EP3021663A4/fr
Application granted granted Critical
Publication of EP3021663B1 publication Critical patent/EP3021663B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
EP14830365.4A 2014-10-05 2014-10-11 Souris transgénique exprimant la lipoprotéine (a) humaine avec gène de la vitamine c désactivé Active EP3021663B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/506,674 US20150074835A1 (en) 2013-09-12 2014-10-05 Transgenic mouse expressing human lipoprotein (a) with disabled vitamin c gene and its use as a disease treatment model
PCT/US2014/060195 WO2016057050A1 (fr) 2014-10-05 2014-10-11 Souris transgénique exprimant la lipoprotéine (a) humaine avec gène de la vitamine c désactivé et son utilisation comme modèle de traitement de maladie

Publications (3)

Publication Number Publication Date
EP3021663A1 EP3021663A1 (fr) 2016-05-25
EP3021663A4 true EP3021663A4 (fr) 2016-09-21
EP3021663B1 EP3021663B1 (fr) 2023-01-18

Family

ID=55660090

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14830365.4A Active EP3021663B1 (fr) 2014-10-05 2014-10-11 Souris transgénique exprimant la lipoprotéine (a) humaine avec gène de la vitamine c désactivé

Country Status (3)

Country Link
EP (1) EP3021663B1 (fr)
RU (1) RU2721254C2 (fr)
WO (1) WO2016057050A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035241A1 (fr) * 1998-01-08 1999-07-15 Aventis Pharmaceuticals Products Inc. Lapin transgenique exprimant une lipoproteine (a) humaine fonctionnelle
US20150074837A1 (en) * 2013-09-12 2015-03-12 Matthias W. Rath Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035241A1 (fr) * 1998-01-08 1999-07-15 Aventis Pharmaceuticals Products Inc. Lapin transgenique exprimant une lipoproteine (a) humaine fonctionnelle
US20150074837A1 (en) * 2013-09-12 2015-03-12 Matthias W. Rath Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHA J, NIEDZWIECKI A, RATH M: "Hypoascorbemia induces atherosclerosis and vascular deposition of lipoprotein(a) in transgenic mice.", AM J CARDIOVASC DIS. 2015 MAR 31, vol. 5, no. 1, 20 March 2015 (2015-03-20), pages 53 - 62, XP055295448 *
EUAN J. RODGER ET AL: "Proteomic Analysis of Aortae from Human Lipoprotein(a) Transgenic Mice Shows an Early Metabolic Response Independent of Atherosclerosis", PLOS ONE, vol. 7, no. 1, 19 January 2012 (2012-01-19), pages e30383, XP055273503, DOI: 10.1371/journal.pone.0030383 *
JOHN CHA ET AL: "Lipoprotein(a) and vitamin C affect the development of breast cancer tumors in Lp(a)+; Gulo-/- mice", INTERNATIONAL JOURNAL OF ONCOLOGY, SEPTEMBER 2016, vol. 49, no. 3, 1 July 2016 (2016-07-01), XP002760783 *
JOHN CHA, M. WAHEED ROOMI, ALEKSANDRA NIEDZWIECKI, MATTHIAS RATH: "Abstract 2288: Lipoprotein(a) and vitamin C affect the development of breast cancer tumors in Lp(a)+; Gulo-/- mice", CANCER RESEARCH; PROCEEDINGS: AACR 106TH ANNUAL MEETING 2015; APRIL 18-22, 2015; PHILADELPHIA, PA, vol. 75, no. 15 Suppl, 1 August 2015 (2015-08-01), XP002760785 *
See also references of WO2016057050A1 *
Y. NAKATA ET AL: "Vulnerable Atherosclerotic Plaque Morphology in Apolipoprotein E-Deficient Mice Unable to Make Ascorbic Acid", CIRCULATION, vol. 105, no. 12, 26 March 2002 (2002-03-26), US, pages 1485 - 1490, XP055295478, ISSN: 0009-7322, DOI: 10.1161/01.CIR.0000012142.69612.25 *

Also Published As

Publication number Publication date
RU2721254C2 (ru) 2020-05-18
EP3021663A1 (fr) 2016-05-25
EP3021663B1 (fr) 2023-01-18
RU2015113820A3 (fr) 2018-06-15
RU2015113820A (ru) 2016-11-10
WO2016057050A1 (fr) 2016-04-14

Similar Documents

Publication Publication Date Title
IL252159B (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
HK1220418A1 (zh) 治療呼吸系統疾病的方法及為此而製的製劑
GB201616616D0 (en) Nasal drug products and methods of their use
GB201403093D0 (en) Therapeutic compounds and their use
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
EP3122754A4 (fr) Utilisation de la plate-forme structurale chimique centrale de fl118 pour produire des dérivés de fl118 pour le traitement d'une maladie humaine
EP3104776A4 (fr) Diagnostic et traitement de troubles respiratoires
EP3230439C0 (fr) Modèle de barrière hémato-encéphalique humaine
EP3030275A4 (fr) Procédé de traitement de maladies des artères périphériques des membres inférieurs
IL248016A0 (en) Effect of lipophilic nutrients on diabetic eye disease
IL250990A0 (en) Materials for human care
EP3134737A4 (fr) Méthodes de diagnostic et de traitement de la maladie coeliaque chez les enfants
EP3030276A4 (fr) Procédé de traitement de maladies des artères périphériques des membres inférieurs
EP3030274A4 (fr) Procédé de traitement de maladies des artères périphériques des membres inférieurs
HK1251265A1 (zh) 感染性疾病的診斷與治療
EP3130582B8 (fr) Composé ayant un effet thérapeutique sur les maladies immunitaires et utilisation de ce composé
ZA201703833B (en) Oral care products and methods of use and manufacture thereof
IL251530B (en) Use of cannabinoids in the treatment of skeletal muscle wasting diseases
EP2949651A4 (fr) Benzothiazoles substitués et leurs appllications thérapeutiques pour le traitement de maladies humaines
PL3151814T3 (pl) Leczenie zmiany skórnej
EP3154637A4 (fr) Traitement de maladies virales de la peau
GB201510808D0 (en) Patient care pathway shape analysis
HK1217919A1 (zh) 種多重功效護膚中藥組合物的製備方法及其應用
HK1257598A1 (zh) 改善心臟病變的藥物及其用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150123

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIC1 Information provided on ipc code assigned before grant

Ipc: A01K 67/027 20060101AFI20160422BHEP

Ipc: A01K 67/00 20060101ALI20160422BHEP

Ipc: A01K 67/033 20060101ALI20160422BHEP

Ipc: C12N 15/00 20060101ALI20160422BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHA, JOHN, CHANG-EUN

Inventor name: RATH, MATTHIAS, W.

Inventor name: NIEDZWIECKI, ALEKSANDRA

A4 Supplementary search report drawn up and despatched

Effective date: 20160823

RIC1 Information provided on ipc code assigned before grant

Ipc: A01K 67/00 20060101ALI20160816BHEP

Ipc: A01K 67/033 20060101ALI20160816BHEP

Ipc: C12N 15/00 20060101ALI20160816BHEP

Ipc: A01K 67/027 20060101AFI20160816BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

R17P Request for examination filed (corrected)

Effective date: 20150123

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180801

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/775 20060101ALI20220712BHEP

Ipc: A01K 67/027 20060101AFI20220712BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20220823

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CHA, JOHN, CHANG-EUN

Inventor name: NIEDZWIECKI, ALEKSANDRA

Inventor name: RATH, MATTHIAS, W.

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014086122

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1544192

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230215

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20230118

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1544192

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230518

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230418

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230518

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230419

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014086122

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118

26N No opposition filed

Effective date: 20231019

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230118